

TecSalud to take part in clinical trial of new German vaccine



TecSalud's Zambrano Hellion Hospital is to be the central site for concentrating and distributing doses of the mRNA vaccine from the Curevac laboratory.

14/09/2020

TecSalud, the health system of **Tecnológico de Monterrey**, has announced that it will be included in a **multi-center study** to develop a **new German vaccine** against **COVID-19** in approximately eight weeks.

*"The complete study worldwide will consist of applying the vaccine to **27,000 people**, of which **2,500** will be in **Nuevo León**, in a coordinated effort between **TecSalud** and the Ministry of Health for the state,"* said Guillermo Torre, Rector of TecSalud.

The **TecSalud Zambrano Hellion Hospital** will be the main site for concentrating doses of the vaccines and distributing them across the state.



TecSalud will form part of the multi-center study for the development of a new German vaccine.

Servando Cardona, National Director of Clinical Research at TecSalud, said that: *“the **mRNA vaccine** from the **Curevac** laboratory is in **Phase 2b/3**, which means it is a step away from going on sale.”*

He also reiterated that *“special **logistics** will be deployed in order to comply with the objective of this protocol, and the necessary ethical aspects will be taken care of so that everything is run to the highest standards of **quality** and patient **safety**.”*

*“At TecSalud, we’ll be taking part with our **hospitals**, and the **Ministry of Health** for **Nuevo León** will be designating application sites, so we’ll be working together in order to reach the goal of recruiting the necessary people,”* said Dr. Torre.



THE ESTIMATED GOAL: JULY 2021

*“You have to go through several processes in order to conclude a study of this type, such as the **safety and effectiveness of the vaccine**, which will be measured for one year after the beginning of the study. After that, it could then start to be sold and produced in large quantities,” explained Dr. Cardona Huerta.*

Guillermo Torre concluded: *“For [TecSalud](#), it’s an honor to have been invited to take part in a **clinical trial** of this size and importance. We have the capacity to do so and will be doing our level best to contribute to the necessary tests for making this vaccine possible.”*

[TecSalud](#) will soon be publishing the **inclusion criteria** for those who wish to take part in this clinical research protocol.

YOU'LL SURELY WANT TO READ THIS TOO: